267
Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R (2001) ICE/caspase-1 inhibitors as
novel anti-inflammatory drugs. Expert Opin Investig Drugs 10:1207–1209
Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open
3:e003573
Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C (2012) In vivo roles of factor XII. Blood
120(22):4296–4303. doi:10.1182/blood-2012-07-292094
Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC (2005) The structure of interleukin2 complexed with its alpha receptor. Science 308:1477–1480
Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res
50(Suppl):S29–S34
Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and
its receptors in inflammatory diseases. Expert Rev Clin Immunol 10:593–619
Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343:227–235
Schreiber S (2007) Crohn’s disease–infliximab, adalimumab and certolizumab-pegol: clinical
value of anti-TNF-alpha treatment. Dtsch Med Wochenschr 132:1770–1774
Scully CC, Blakeney JS, Singh R, Hoang HN, Abbenante G, Reid RC, Fairlie DP (2010) Selective
hexapeptide agonists and antagonists for human complement C3a receptor. J Med Chem
53:4938–4948
Semple G, Ashworth DM, Batt AR, Baxter AJ, Benzies DW, Elliot LH, Evans DM, Franklin
RJ, Hudson P, Jenkins PD et al (1998) Peptidomimetic aminomethylene ketone inhibitors of
interleukin- 1 beta-converting enzyme (ICE). Bioorg Med Chem Lett 8:959–964
Shahripour AB, Plummer MS, Lunney EA, Albrecht HP, Hays SJ, Kostlan CR, Sawyer TK, Walker
NP, Brady KD, Allen HJ, Talanian RV, Wong WW, Humblet C (2002) Structure-based design
of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med
Chem 10:31–40
Smith LS, Nelson M, Dolder CR (2010) Certolizumab pegol: a TNF-{alpha} antagonist for the
treatment of moderate-to-severe Crohn’s disease. Ann Pharmacother 44:333–342
Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C, Juge-Aubry
CE, Dayer JM, Nicklin MJ, Meda P, Rohner-Jeanrenaud F, Meier CA (2006) Interleukin-1
receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity
in rodents. Diabetologia 49:387–393
Soper DL, Sheville JX, O’Neil SV, Wang Y, Laufersweiler MC, Oppong KA, Wos JA, Ellis CD,
Baize MW, Chen JJ, Fancher AN, Lu W, Suchanek MK, Wang RL, Schwecke WP, Cruze CA,
Buchalova M, Belkin M, Wireko F, Ritter A, De B, Wang D, Demuth TP Jr (2006) Synthesis
and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1beta
converting enzyme (ICE) inhibitors. Bioorg Med Chem 14:7880–7892
Soter NA, Austen KF (1976) The diversity of mast cell-derived mediators: implications for acute,
subacute, and chronic cutaneous inflammatory disorders. J Invest Dermatol 67(3):313–319
Tesch H, König W (1979) Origin and biological role of lipid mediators during inflammation
(author’s transl). Immun Infekt 7(5):157–164
Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I (2010) Structure and
function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci
67:2909–2935
Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253–278
Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, Ravizza T (2010) ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig
Drugs 11:43–50
Wagner G, Laufer S (2006) Small molecular anti-cytokine agents. Med Res Rev 26:1–62
Wang YS, Zhang Y, Liang H (2010) Role of microRNAs in diabetes and diabetes-associated complications. Sheng Li Ke Xue Jin Zhan 41:133–136
Waugh J, Perry CM (2005) Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 19:189–202
10 Anti-inflammatory Molecules: Immune System Mediators
Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R (2001) ICE/caspase-1 inhibitors as
novel anti-inflammatory drugs. Expert Opin Investig Drugs 10:1207–1209
Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open
3:e003573
Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C (2012) In vivo roles of factor XII. Blood
120(22):4296–4303. doi:10.1182/blood-2012-07-292094
Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC (2005) The structure of interleukin2 complexed with its alpha receptor. Science 308:1477–1480
Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res
50(Suppl):S29–S34
Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and
its receptors in inflammatory diseases. Expert Rev Clin Immunol 10:593–619
Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343:227–235
Schreiber S (2007) Crohn’s disease–infliximab, adalimumab and certolizumab-pegol: clinical
value of anti-TNF-alpha treatment. Dtsch Med Wochenschr 132:1770–1774
Scully CC, Blakeney JS, Singh R, Hoang HN, Abbenante G, Reid RC, Fairlie DP (2010) Selective
hexapeptide agonists and antagonists for human complement C3a receptor. J Med Chem
53:4938–4948
Semple G, Ashworth DM, Batt AR, Baxter AJ, Benzies DW, Elliot LH, Evans DM, Franklin
RJ, Hudson P, Jenkins PD et al (1998) Peptidomimetic aminomethylene ketone inhibitors of
interleukin- 1 beta-converting enzyme (ICE). Bioorg Med Chem Lett 8:959–964
Shahripour AB, Plummer MS, Lunney EA, Albrecht HP, Hays SJ, Kostlan CR, Sawyer TK, Walker
NP, Brady KD, Allen HJ, Talanian RV, Wong WW, Humblet C (2002) Structure-based design
of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med
Chem 10:31–40
Smith LS, Nelson M, Dolder CR (2010) Certolizumab pegol: a TNF-{alpha} antagonist for the
treatment of moderate-to-severe Crohn’s disease. Ann Pharmacother 44:333–342
Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C, Juge-Aubry
CE, Dayer JM, Nicklin MJ, Meda P, Rohner-Jeanrenaud F, Meier CA (2006) Interleukin-1
receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity
in rodents. Diabetologia 49:387–393
Soper DL, Sheville JX, O’Neil SV, Wang Y, Laufersweiler MC, Oppong KA, Wos JA, Ellis CD,
Baize MW, Chen JJ, Fancher AN, Lu W, Suchanek MK, Wang RL, Schwecke WP, Cruze CA,
Buchalova M, Belkin M, Wireko F, Ritter A, De B, Wang D, Demuth TP Jr (2006) Synthesis
and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1beta
converting enzyme (ICE) inhibitors. Bioorg Med Chem 14:7880–7892
Soter NA, Austen KF (1976) The diversity of mast cell-derived mediators: implications for acute,
subacute, and chronic cutaneous inflammatory disorders. J Invest Dermatol 67(3):313–319
Tesch H, König W (1979) Origin and biological role of lipid mediators during inflammation
(author’s transl). Immun Infekt 7(5):157–164
Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I (2010) Structure and
function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci
67:2909–2935
Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253–278
Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, Ravizza T (2010) ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig
Drugs 11:43–50
Wagner G, Laufer S (2006) Small molecular anti-cytokine agents. Med Res Rev 26:1–62
Wang YS, Zhang Y, Liang H (2010) Role of microRNAs in diabetes and diabetes-associated complications. Sheng Li Ke Xue Jin Zhan 41:133–136
Waugh J, Perry CM (2005) Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 19:189–202
10 Anti-inflammatory Molecules: Immune System Mediators